Lymphoma

Adult survivors of childhood cancer with a high risk of cardiovascular disease may not be receiving proper cardiac testing, according to study findings published in JAMA Network Open.

Curative potential at a longer follow-up, logistics and patient risk and eligibility are all important considerations when sequencing bispecific antibodies and chimeric antigen receptor T-cell therapy for advanced large B-cell lymphoma.

In this video, Stephen M. Ansell, MD, PhD, discussed updated study results showing an advantage of nivolumab-chemo over brentuximab vedotin-chemo in both younger and older patients.

In this video, Brian T. Hill, MD, PhD, discusses important research on bispecific antibodies for the treatment of lymphoma presented at ASH Annual Meeting and Exhibition.

SAN DIEGO — Patients with relapsed large B-cell lymphoma who achieved a complete remission had a reduced relapse rate and improved PFS with autologous transplant, according to study findings presented at ASH Annual Meeting and Exposition.

Ibrutinib plus venetoclax demonstrated superior PFS and a higher complete response rate compared with ibrutinib plus placebo in patients with relapsed or refractory mantle cell lymphoma, according to study results.

In a special scientific session on race and science at ASH Annual Meeting an Exposition, Saad Z. Usmani, MD, MBA, FACP, FRCP, examined clinical trial inclusion from an investigator’s perspective.

SAN DIEGO — Patients with lymphoma who receive palliative care incur significantly lower total hospitalization charges than patients who do not, according to study findings presented at ASH Annual Meeting and Exposition.

Chimeric antigen receptor T cells have improved survival rates as second-line therapy for individuals with high-risk diffuse large B-cell lymphoma, but available therapies lack cost-effectiveness at current prices, study results showed.

The FDA granted accelerated approval to pirtobrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.